SOURCE-LINKED INTELLIGENCE

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome

CORDIS · observation · Publication date unknown

trial design, we will evaluate several multiple promising, non-invasive, liquid biopsy-based technologies in the three most common LS cancer types for an early-stage cancers detection. By leveraging Artificial intelligence (AI), we will identify traces of cancer, ensuring applicability to diverse healthcare systems. A comprehensive framework will assess the broader socio-economic and ethical impacts, ensuring that the solutions align with the societal values and healthcare needs. Parterning with leading biomarker companies (GNT, MSInsight, MSICare, MSIPlus and Elypta), we aim to deliver a multi-omic solution for affordable, accessible and effective test to advance the detection of heritable cancer detections in LS. This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers). Liquid biopsy; microsatellite instability markers; metabolomic markers

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

13606320.25

unit

EUR